Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EBS Emergent Biosolutions	$7.34 +0.1%	$6.40	$4.02 ▼ $15.10	$397.86M	2.09	1.70 million shs	1.05 million shs
RGLS Regulus Therapeutics	$8.16	$8.04	$0.83 ▼ $8.35	$564.92M	0.35	996,921 shs	N/A
RIGL Rigel Pharmaceuticals	$18.88 -3.7%	$19.49	$8.61 ▼ $29.82	$350.30M	1.26	210,713 shs	212,770 shs
VSTM Verastem	$4.68 -1.3%	$6.11	$2.10 ▼ $9.10	$260.46M	0.71	1.29 million shs	1.21 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EBS Emergent Biosolutions	+0.14%	+5.01%	+9.88%	+67.92%	-20.99%
RGLS Regulus Therapeutics	0.00%	0.00%	+0.12%	+358.43%	+363.64%
RIGL Rigel Pharmaceuticals	-3.67%	-0.19%	-10.90%	+13.19%	+119.79%
VSTM Verastem	-1.27%	-1.68%	-21.61%	+0.86%	+71.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EBS Emergent Biosolutions	4.1774 of 5 stars	3.5	1.0	4.6	1.5	2.5	1.3
RGLS Regulus Therapeutics	1.5035 of 5 stars	2.1	5.0	0.0	0.0	3.3	0.0
RIGL Rigel Pharmaceuticals	3.0024 of 5 stars	3.2	0.0	0.0	2.3	1.7	3.1
VSTM Verastem	3.126 of 5 stars	3.5	5.0	0.0	1.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EBS Emergent Biosolutions	3.00	Buy	$14.33	95.28% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$36.40	92.80% Upside
VSTM Verastem	3.00	Buy	$13.38	185.79% Upside

Current Analyst Ratings Breakdown

Latest RGLS, RIGL, EBS, and VSTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/7/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EBS Emergent Biosolutions	$1.04B	0.38	$1.92 per share	3.82	$8.91 per share	0.82
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
RIGL Rigel Pharmaceuticals	$179.28M	1.88	$1.04 per share	18.17	$0.19 per share	99.37
VSTM Verastem	$10K	25,716.60	N/A	N/A	($0.65) per share	-7.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.55	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$2.07	9.12	17.98	N/A	18.31%	-655.26%	24.47%	8/5/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.20	N/A	N/A	N/A	N/A	-2,003.62%	-127.97%	8/6/2025 (Estimated)

Latest RGLS, RIGL, EBS, and VSTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	EBS Emergent Biosolutions	$0.21	N/A	N/A	N/A	$148.55 million	N/A
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.42	N/A	N/A	N/A	$64.58 million	N/A
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/6/2025	Q1 2025	RIGL Rigel Pharmaceuticals	$0.14	$0.63	+$0.49	$0.63	$43.87 million	$53.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EBS Emergent Biosolutions	1.20	6.32	3.51
RGLS Regulus Therapeutics	N/A	16.31	16.31
RIGL Rigel Pharmaceuticals	2.42	2.20	2.13
VSTM Verastem	N/A	3.50	3.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EBS Emergent Biosolutions	78.40%
RGLS Regulus Therapeutics	92.38%
RIGL Rigel Pharmaceuticals	66.23%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
EBS Emergent Biosolutions	1.20%
RGLS Regulus Therapeutics	4.35%
RIGL Rigel Pharmaceuticals	9.48%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.87 million	16.18 million	Optionable
VSTM Verastem	50	54.95 million	53.80 million	Optionable

RGLS, RIGL, EBS, and VSTM Headlines

Recent News About These Companies

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial ...

July 11 at 6:28 PM | gurufocus.com

Verastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock News

July 11 at 6:28 PM | gurufocus.com

Verastem stock rises after LGSOC treatment data published in medical journal

July 11 at 5:15 PM | in.investing.com

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

July 11 at 5:07 PM | businesswire.com

Verastem, Inc. (VSTM) - Yahoo Finance

July 9 at 5:00 PM | finance.yahoo.com

Verastem KRAS-Mutant Ovarian Cancer Treatment Activity Affirmed in Investigator-Initiated Study

July 8, 2025 | precisionmedicineonline.comP

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 8, 2025 | businesswire.com

BTIG Remains a Buy on Verastem (VSTM)

July 4, 2025 | theglobeandmail.com

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment

July 4, 2025 | tipranks.com

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

June 30, 2025 | businesswire.com

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Brokerages

June 28, 2025 | marketbeat.com

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

June 26, 2025 | seekingalpha.com

FY2025 EPS Estimates for Verastem Cut by Cantor Fitzgerald

June 26, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Morningstar

June 26, 2025 | morningstar.comM

Royal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock Price

June 25, 2025 | marketbeat.com

Insider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)

June 24, 2025 | gurufocus.com

Verastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 Shares

June 24, 2025 | marketbeat.com

Dan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock

June 24, 2025 | marketbeat.com

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

June 24, 2025 | businesswire.com

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges

June 15, 2025 | investing.com

Verastem reports promising cancer drug trial results

June 3, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGLS, RIGL, EBS, and VSTM Company Descriptions

Emergent Biosolutions NYSE:EBS

$7.34 +0.01 (+0.14%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$7.28 -0.06 (-0.76%)

As of 07/11/2025 07:50 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$18.88 -0.72 (-3.67%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.92 +0.05 (+0.24%)

As of 07/11/2025 04:34 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Verastem NASDAQ:VSTM

$4.68 -0.06 (-1.27%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$4.76 +0.08 (+1.71%)

As of 07/11/2025 07:56 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time